Top-Rated StocksTop-RatedNASDAQ:DICE DICE Therapeutics (DICE) Stock Forecast, Price & News $32.81 -0.34 (-1.03%) (As of 05/26/2023 ET) Add Compare Share Share Today's Range$32.14▼$33.6950-Day Range$25.86▼$38.2452-Week Range$12.64▼$45.99Volume212,713 shsAverage Volume452,437 shsMarket Capitalization$1.57 billionP/E RatioN/ADividend YieldN/APrice Target$62.60 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media DICE Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.91 Rating ScoreUpside/Downside90.8% Upside$62.60 Price TargetShort InterestBearish20.83% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.66Based on 16 Articles This WeekInsider TradingAcquiring Shares$10.24 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($2.57) to ($3.57) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.30 out of 5 starsMedical Sector323rd out of 1,012 stocksPharmaceutical Preparations Industry137th out of 495 stocks 4.5 Analyst's Opinion Consensus RatingDICE Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.91, and is based on 10 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $62.60, DICE Therapeutics has a forecasted upside of 90.8% from its current price of $32.81.Amount of Analyst CoverageDICE Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted20.83% of the float of DICE Therapeutics has been sold short.Short Interest Ratio / Days to CoverDICE Therapeutics has a short interest ratio ("days to cover") of 15.2, which indicates bearish sentiment.Change versus previous monthShort interest in DICE Therapeutics has recently decreased by 8.98%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldDICE Therapeutics does not currently pay a dividend.Dividend GrowthDICE Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DICE. Previous Next 2.0 News and Social Media Coverage News SentimentDICE Therapeutics has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for DICE Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 11 people have searched for DICE on MarketBeat in the last 30 days. This is a decrease of -15% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added DICE Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, DICE Therapeutics insiders have bought 82.48% more of their company's stock than they have sold. Specifically, they have bought $10,239,252.00 in company stock and sold $5,611,071.00 in company stock.Percentage Held by InsidersOnly 4.90% of the stock of DICE Therapeutics is held by insiders.Percentage Held by Institutions91.51% of the stock of DICE Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for DICE Therapeutics are expected to decrease in the coming year, from ($2.57) to ($3.57) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DICE Therapeutics is -15.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of DICE Therapeutics is -15.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDICE Therapeutics has a P/B Ratio of 2.86. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About DICE Therapeutics (NASDAQ:DICE) StockDICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17, which is a validated drug target implicated in a various immunology indications. It is also developing oral therapeutic candidates targeting a4ß7 integrin for the treatment of inflammatory bowel diseases, as well as targeting aVß1/aVß6 integrin for the treatment of idiopathic pulmonary fibrosis. In addition, the company focuses on immuno-oncology for antibody therapeutics. The company was incorporated in 2013 and is headquartered in South San Francisco, California.Read More Receive DICE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DICE Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address DICE Stock News HeadlinesMay 26, 2023 | americanbankingnews.comDICE Therapeutics (NASDAQ:DICE) Now Covered by Wells Fargo & CompanyMay 25, 2023 | msn.comWells Fargo Initiates Coverage of DICE Therapeutics (DICE) with Equal-Weight RecommendationMay 28, 2023 | Stocks To Trade (Ad)3 Free Stock Picks per DayUsing our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.May 24, 2023 | msn.comDICE Therapeutics equalweight at Wells Fargo on lack of catalystsMay 24, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Hold Rating for Sana Biotechnology (SANA)May 24, 2023 | americanbankingnews.comDICE Therapeutics (NASDAQ:DICE) Shares Gap Up to $32.66May 23, 2023 | proactiveinvestors.comDICE Therapeutics psoriasis treatment has blockbuster potential, analysts sayMay 23, 2023 | americanbankingnews.comDICE Therapeutics (NASDAQ:DICE) Receives New Coverage from Analysts at Canaccord Genuity GroupMay 28, 2023 | Stocks To Trade (Ad)3 Free Stock Picks per DayUsing our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.May 23, 2023 | msn.comCanaccord Genuity Initiates Coverage of DICE Therapeutics (DICE) with Buy RecommendationMay 22, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Their Buy Rating for Gracell Biotechnologies (GRCL)May 19, 2023 | americanbankingnews.comEquities Analysts Issue Forecasts for DICE Therapeutics, Inc.'s FY2023 Earnings (NASDAQ:DICE)May 18, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for MiNK Therapeutics (INKT)May 18, 2023 | americanbankingnews.comAnalysts Set DICE Therapeutics, Inc. (NASDAQ:DICE) Price Target at $64.63May 15, 2023 | markets.businessinsider.comTrevi Therapeutics (TRVI) Receives a Rating Update from a Top AnalystMay 15, 2023 | markets.businessinsider.comDice Therapeutics (DICE) Receives a Rating Update from a Top AnalystMay 12, 2023 | msn.comHC Wainwright & Co. Reiterates DICE Therapeutics (DICE) Buy RecommendationMay 12, 2023 | finanznachrichten.deDICE Therapeutics, Inc.: DICE Therapeutics Reports First Quarter 2023 Financial Results and Recent HighlightsMay 12, 2023 | markets.businessinsider.comH.C. Wainwright Remains a Buy on Dice Therapeutics (DICE)May 12, 2023 | americanbankingnews.comDICE Therapeutics, Inc. (NASDAQ:DICE) Director Sells $3,238,575.47 in StockMay 11, 2023 | msn.comRecap: DICE Therapeutics Q1 EarningsMay 11, 2023 | seekingalpha.comDICE Therapeutics GAAP EPS of -$0.54May 11, 2023 | finance.yahoo.comDICE Therapeutics Reports First Quarter 2023 Financial Results and Recent HighlightsMay 10, 2023 | benzinga.comDICE Therapeutics Board Member Trades Company's StockMay 8, 2023 | msn.comDICE Therapeutics: Worth A Roll At The Right PriceMay 8, 2023 | americanbankingnews.comInsider Selling: DICE Therapeutics, Inc. (NASDAQ:DICE) CMO Sells $365,400.00 in StockMay 8, 2023 | americanbankingnews.comInsider Selling: DICE Therapeutics, Inc. (NASDAQ:DICE) CFO Sells $685,312.50 in StockSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive DICE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DICE Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address DICE Company Calendar Last Earnings3/15/2023Today5/28/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DICE CUSIPN/A CIK1645569 Webwww.dicemolecules.com Phone650-566-1420FaxN/AEmployees46Year FoundedN/APrice Target and Rating Average Stock Price Forecast$62.60 High Stock Price Forecast$77.00 Low Stock Price Forecast$38.00 Forecasted Upside/Downside+90.8%Consensus RatingModerate Buy Rating Score (0-4)2.91 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($2.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-83,890,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-22.01% Return on Assets-20.70% Debt Debt-to-Equity RatioN/A Current Ratio32.44 Quick Ratio32.44 Sales & Book Value Annual Sales$1.13 million Price / Sales1,385.86 Cash FlowN/A Price / Cash FlowN/A Book Value$11.46 per share Price / Book2.86Miscellaneous Outstanding Shares47,730,000Free Float45,392,000Market Cap$1.57 billion OptionableNot Optionable Beta0.69 Key ExecutivesDr. J. Kevin Judice Ph.D. (Age 58)Founder, CEO & Director Comp: $765.04kMr. Scott RobertsonChief Bus. & Financial OfficerDr. Timothy Lu M.D. (Age 48)Ph.D., Chief Medical Officer Comp: $660.44kDr. John R. Jacobsen Ph.D. (Age 54)Chief Scientific Officer Ms. Mary Riley J.D.Gen. CounselMr. Venkat Thalladi Ph.D.Sr. VP of CMCMr. Paul FathereeSr. VP of Medicinal ChemistryMore ExecutivesKey CompetitorsAurinia PharmaceuticalsNASDAQ:AUPHZentalis PharmaceuticalsNASDAQ:ZNTLIronwood PharmaceuticalsNASDAQ:IRWDGeronNASDAQ:GERNFibroGenNASDAQ:FGENView All CompetitorsInsiders & InstitutionsProShare Advisors LLCSold 1,027 shares on 5/26/2023Ownership: 0.016%JPMorgan Chase & Co.Bought 8,775 shares on 5/18/2023Ownership: 0.097%New York State Common Retirement FundSold 3,733 shares on 5/18/2023Ownership: 0.040%ArrowMark Colorado Holdings LLCSold 2,622 shares on 5/16/2023Ownership: 0.864%Jane Street Group LLCSold 3,410 shares on 5/16/2023Ownership: 0.027%View All Insider TransactionsView All Institutional Transactions DICE Stock - Frequently Asked Questions Should I buy or sell DICE Therapeutics stock right now? 11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for DICE Therapeutics in the last twelve months. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DICE shares. View DICE analyst ratings or view top-rated stocks. What is DICE Therapeutics' stock price forecast for 2023? 11 Wall Street research analysts have issued 12-month target prices for DICE Therapeutics' shares. Their DICE share price forecasts range from $38.00 to $77.00. On average, they predict the company's share price to reach $62.60 in the next twelve months. This suggests a possible upside of 90.8% from the stock's current price. View analysts price targets for DICE or view top-rated stocks among Wall Street analysts. How have DICE shares performed in 2023? DICE Therapeutics' stock was trading at $31.20 on January 1st, 2023. Since then, DICE shares have increased by 5.2% and is now trading at $32.81. View the best growth stocks for 2023 here. Are investors shorting DICE Therapeutics? DICE Therapeutics saw a decline in short interest in May. As of May 15th, there was short interest totaling 8,010,000 shares, a decline of 9.0% from the April 30th total of 8,800,000 shares. Based on an average trading volume of 526,900 shares, the short-interest ratio is currently 15.2 days. Currently, 20.8% of the company's stock are short sold. View DICE Therapeutics' Short Interest. When is DICE Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our DICE earnings forecast. How were DICE Therapeutics' earnings last quarter? DICE Therapeutics, Inc. (NASDAQ:DICE) announced its quarterly earnings results on Wednesday, March, 15th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.49) by $0.02. What ETFs hold DICE Therapeutics' stock? ETFs with the largest weight of DICE Therapeutics (NASDAQ:DICE) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), First Trust Multi-Manager Small Cap Opportunities ETF (MMSC), Principal Healthcare Innovators ETF (BTEC), iShares U.S. Pharmaceuticals ETF (IHE), iShares Micro-Cap ETF (IWC) and Invesco Nasdaq Biotechnology ETF (IBBQ). When did DICE Therapeutics IPO? (DICE) raised $160 million in an initial public offering (IPO) on Wednesday, September 15th 2021. The company issued 10,000,000 shares at a price of $15.00-$17.00 per share. What is DICE Therapeutics' stock symbol? DICE Therapeutics trades on the NASDAQ under the ticker symbol "DICE." Who are DICE Therapeutics' major shareholders? DICE Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include FMR LLC (11.90%), Avoro Capital Advisors LLC (8.28%), Price T Rowe Associates Inc. MD (6.82%), BlackRock Inc. (6.31%), Armistice Capital LLC (2.88%) and Baker BROS. Advisors LP (2.17%). Insiders that own company stock include James Paul Scopa, John R Jacobsen, Kevin Judice, Lu Timothy, Ra Capital Management, LP, Richard H Scheller and Scott M Robertson. View institutional ownership trends. How do I buy shares of DICE Therapeutics? Shares of DICE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is DICE Therapeutics' stock price today? One share of DICE stock can currently be purchased for approximately $32.81. How much money does DICE Therapeutics make? DICE Therapeutics (NASDAQ:DICE) has a market capitalization of $1.57 billion and generates $1.13 million in revenue each year. The company earns $-83,890,000.00 in net income (profit) each year or ($2.18) on an earnings per share basis. How can I contact DICE Therapeutics? DICE Therapeutics' mailing address is 279 E. GRAND AVENUE SUITE 300 LOBBY B, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.dicemolecules.com. The company can be reached via phone at 650-566-1420 or via email at investors@dicetx.com. This page (NASDAQ:DICE) was last updated on 5/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DICE Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.